<unk> , sold under the brand name Yescarta, is a treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow.<unk>  treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities. Due to CD19 is a pan-B cell marker, the T-cells that are engineered to target CD19 receptors on the cancerous B cells also influence normal B cells, except some plasma cells.
Axicabtagene ciloleucel
Efgartigimod alfa
Brigatinib
Turoctocog alfa
Etalocib
Seviteronel
Encorafenib
Tucatinib